Kapruvia (Difelikefalin)

Difelikefalin selectively activates peripheral kappa‑opioid receptors on sensory nerves. This activation modulates the transmission of itch signals to the brain, reducing the perception of itch without producing central opioid effects, because the compound largely remains outside the central nervous system.

The dosage of Kapruvia is determined by the prescribing healthcare professional based on the patient’s clinical condition, weight, and response to therapy. The prescriber will specify the exact amount and frequency in the treatment plan.

Safety data for Kapruvia during pregnancy and lactation are limited. It is generally advised to avoid use unless the potential benefit to the mother clearly outweighs any possible risk to the fetus or infant. Consultation with a specialist is recommended.

To request Kapruvia, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics if needed), and any required import documentation.

Kapruvia belongs to the class of selective kappa‑opioid receptor agonists, offering a mechanism distinct from antihistamines or traditional opioids. Compared with non‑selective agents, it provides targeted peripheral itch control with a lower risk of central opioid side effects, making it a valuable option when conventional therapies are insufficient.

Kapruvia must be stored at 2‑8 °C (refrigerated). Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Follow all cold‑chain requirements during transport and handling to maintain product stability.

Kapruvia is given as an intravenous injection. The healthcare professional prepares the injectable solution according to the prescribed dose and administers it directly into a vein, typically in a clinical setting such as a dialysis unit or hospital.

Serious adverse reactions include severe hypersensitivity (e.g., anaphylaxis), significant hypotension, and respiratory depression. Patients should be monitored for signs of allergic response, sudden drops in blood pressure, or breathing difficulties, and treatment should be stopped immediately if these occur.

Kapruvia is contraindicated in individuals with known hypersensitivity to difelikefalin or any component of the formulation. Caution is also advised for patients receiving other opioid agonists, those with uncontrolled severe hypotension, or anyone for whom the risk‑benefit profile is unfavorable.